Compare CTM & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTM | ELOX |
|---|---|---|
| Founded | 2019 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.1M | 60.3M |
| IPO Year | 2022 | 2013 |
| Metric | CTM | ELOX |
|---|---|---|
| Price | $0.54 | $13.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $38.25 |
| AVG Volume (30 Days) | ★ 326.9K | 17.7K |
| Earning Date | 11-06-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.33 | 41.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $52,866,001.00 | N/A |
| Revenue This Year | $6.00 | N/A |
| Revenue Next Year | $7.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.10 | N/A |
| 52 Week Low | $0.48 | $10.00 |
| 52 Week High | $1.36 | $23.40 |
| Indicator | CTM | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 32.73 | 40.05 |
| Support Level | $0.48 | $10.74 |
| Resistance Level | $0.66 | $14.65 |
| Average True Range (ATR) | 0.02 | 1.28 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 27.14 | 21.89 |
Castellum Inc is focused on building a successful technology services, solutions, and products company in the areas of cybersecurity, IT, electronic warfare, information warfare, system modernization, and information operations with businesses in the defense, federal, civilian, and commercial markets. Services include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and model-based systems engineering. The company maintains one operating and reportable segment, which is the delivery of products and services in the areas of information technology, electronic warfare, information warfare and cybersecurity in the governmental and commercial markets.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.